NCT04728854 is a clinical trial in Bullous Pemphigoid, sponsored by Emory University.

Who is sponsoring NCT04728854?

NCT04728854 is sponsored by Emory University.

What condition does NCT04728854 study?

NCT04728854 studies Bullous Pemphigoid.

Is NCT04728854 still recruiting?

NCT04728854 is currently completed. Last updated 13 October 2023.

Last reviewed 2023-10-13 · How we verify

NCT04728854

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Telederm and Bullous Pemphigoid

Completed Last updated 13 October 2023

What this trial tests

trial in Bullous Pemphigoid in 21 participants. Completed in 6 October 2023.

Timeline

15 March 2021

Primary endpoint
6 October 2023

6 October 2023

Quick facts

Lead sponsor	Emory University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	21
Start date	15 March 2021
Primary completion	6 October 2023
Estimated completion	6 October 2023
Sites	1 location across United States

Conditions studied

Bullous Pemphigoid — all drugs for Bullous Pemphigoid →

Sponsor

Emory University

Who can join

18 and older, any sex, with Bullous Pemphigoid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to improve the quality of future clinical trials in bullous pemphigoid (BP), the investigators will monitor repeated measurement data from patients with BP on standard-of-care treatments at four week intervals for four months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bullous Pemphigoid

Currently open trials in the same condition.

NCT06479018 — Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid · NA · recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04728854 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 13 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04728854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing